One week after confirming Tang Capital’s Concentra Biosciences proposal to buy Atea Pharmaceuticals, the Boston-based biotech said its board has rejected the unsolicited offer. The company, which has struggled to cross the finish line in COVID-19 and has reworked its priorities in recent quarters, said its board “unanimously concluded” the Concentra proposal was “not in the best interests of Atea or its shareholders.”(Endpoints News)
Eli Lilly partnered with Shenzhen-based Xtalpi, an AI-powered drug discoverer, in a deal worth up to $250 million. Xtalpi said the drug candidates will target a disease that currently has no medicine available. (Forbes)
A growing movement of therapy has suggested that the body, rather than the mind, is the origin of our feelings. Therapists and clients describe how trauma gets stuck within and how somatic therapy can provide release. (The New York Times)
GE HealthCare announced that the Food and Drug Administration issued a 510(k) clearance for Precision DL. The company’s deep learning-based image processing software is designed to enhance the quality of PET/CT imaging. (Seeking Alpha)
ESPN anchor and COVID-19 vaccine skeptic Sage Steele’s legal battle with Disney has heated up. At issue in Steele’s suit is her first amendment rights and not her vaccination status as she was fully compliant with Disney’s vaccine policy. (Variety)
